Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - jayempi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp29e53310e209535224a929c7efb5c5b7
identifier: http://ema.europa.eu/identifier
/EU/1/21/1557/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Jayempi 10 mg/ml oral suspension
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-29e53310e209535224a929c7efb5c5b7
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1557/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - jayempi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Jayempi 10 mg/ml oral suspension contains the active substance azathioprine. It belongs to a group of medicines called immunosuppressants. These medicines reduce the activity of your immune system (the body s defences).
Jayempi is used to:
Do not take Jayempi
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Jayempi:
If you notice any unexplained bruising or bleeding during treatment or you have signs of infection, contact your doctor immediately.
Infections
Treatment with Jayempi increases the risk of infections and the infections may become more serious (see also section 4). Because chickenpox (caused by varicella-zoster virus VZV) can be serious when you are taking Jayempi, you should avoid any contact with people suffering from chickenpox (varicella) or shingles (herpes zoster). Tell your doctor if you come into contact with anyone who has chickenpox or shingles. Your doctor will decide if you need antiviral treatment and if you should stop treatment with Jayempi.
Blood tests
You will need a blood test to check your blood cell count at least once a week during the first 8 weeks of treatment. You may need blood tests more often if you:
After 8 weeks, your blood count should be checked once a month or at least every 3 months.
NUDT15-gene mutation If you have an inherited mutation in the NUDT15-gene (a gene which is involved in the break-down of azathioprine in the body), you have a higher risk of infections and hair loss and your doctor may in this case give you a lower dose. Your doctor may also ask you to have a test to check how well your body will be able to break-down this medicine. Your doctor may change your dose after these tests.
Taking Jayempi may increase your risk of:
Other medicines and Jayempi
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Jayempi can affect the way some medicines work. Also some other medicines can affect the way Jayempi works:
Before an operation tell your doctor that you are taking azathioprine because muscle relaxants used during anaesthesia may interact with azathioprine.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Women taking Jayempi or the female partners of men taking Jayempi must not become pregnant during treatment and for 6 months afterwards. Both men and women taking Jayempi must use effective contraception during treatment with and for 6 months afterwards. Intrauterine devices are not suitable for contraception in women taking Jayempi (or in women whose male partners are taking Jayempi).
If you are planning to have a baby, talk to your doctor. If you are pregnant, you should only take Jayempi if your doctor tells you to. In case you are or believe you might be pregnant you must inform your doctor immediately.
Changes in blood counts can occur in newborn babies of mothers who received azathioprine during pregnancy. Regular checks of blood counts during pregnancy are recommended.
Do not breast-feed during therapy with Jayempi. This is because small amounts may pass into the mother s milk.
Driving and using machines Do not drive or use machines if you are affected or if you feel dizzy while taking this medicine.
Jayempi contains sodium benzoate (E211) This medicine contains 1.5 mg sodium benzoate (E211) in each ml. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
Jayempi contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure
Dose
The dose of Jayempi depends on your weight, the condition being treated, how well it is being controlled and your overall health. Your doctor will work out the dose that is right for you and may adjust it during treatment. The doctor will tell you how long you should continue taking the medicine.
For preventing organ rejection after transplantation, the usual starting dose is 5 mg per kg of your weight each day and the dose is then reduced after a few weeks or months to between 1 and 4 mg per kg of your weight each day. The dose for other conditions is usually between 1 and 3 mg per kg of your weight each day.
Kidney/ liver disease Your dose may be reduced if you have kidney or liver disease.
Use in children The dose for children and adolescents is the same as the adult dose. The safety and efficacy of azathioprine in children have not yet been established for the treatment of chronic joint inflammation (juvenile idiopathic arthritis) and multiple sclerosis. Therefore, the use of Jayempi for these conditions in children is not recommended.
Use in elderly patients A reduced dose may be needed.
Jayempi with food and drink
Jayempi should be taken at least 1 hour before or 2 hours after a meal or milk. Check with your doctor or pharmacist if you are not sure.
You should drink some water after each dose of Jayempi. This helps to make sure that the full dose of the medicine enters your digestive system.
Handling
Your pack contains a 200-ml bottle of medicine, cap, a bottle adaptor and two dosing syringes (a 3-ml syringe and a 10-ml syringe). Always use the syringes provided to take your medicine.
For example:
For example:
It is important to use the correct dosing syringe for your medicine. Your doctor or pharmacist will tell you which syringe to use depending on the dose prescribed for you.
If you are taking or giving the medicine to a child or somebody else, wash your hands before and after. Wipe up spillages immediately. To decrease the risk of coming into contact with the medicine, use disposable gloves when handling Jayempi. If Jayempi comes into contact with skin, eyes or nose, wash the area immediately and thoroughly with soap and water.
When you use the medicine follow the instructions below:
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5
Repeat the above for each dose as instructed by your doctor or pharmacist.
If you take more Jayempi than you should
If you take more Jayempi than you should, talk to your doctor or go to a hospital immediately. Take the medicine pack with you.
The most likely effect of an overdose is bone marrow suppression reaching its maximum 9-14 days after dosing. Bone marrow suppression reduces your blood counts and in severe cases lead to dangerous infections and other serious effects. Some symptoms of bone marrow suppression include feeling tired, ulcers in the mouth and throat, fever and infection, and unexplained bruising and bleeding.
If you forget to take Jayempi
Do not take a double dose to make up for a forgotten dose. Take the next dose as usual. If you have forgotten more than one dose, speak with your doctor.
If you stop taking Jayempi
Treatment with Jayempi should always be under close medical supervision. Talk to your doctor, if you wish to interrupt or stop the treatment.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any of the following serious side effects, stop taking Jayempi and talk to your doctor or go to hospital immediately:
general tiredness, dizziness, feeling sick (nausea), being sick (vomiting) or diarrhoea, high temperature (fever), shivering or chills, redness of the skin, skin nodules, or a skin rash, pain in the muscles or joints, changes in the colour of your urine (kidney problems), confusion, feeling light headed or weak (caused by low blood pressure).
If you get any of the following serious side effects, talk to your doctor or go to hospital immediately:
Other side effects include:
Very common (may affect more than 1 in 10 people)
Suppression of bone marrow function generally returns to normal when the dose is adjusted. Signs of abnormal bone marrow function may be: increased susceptibility to infections, ulcers in the mouth and throat, increased bleeding, fatigue and poor mental and physical performance
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Liver damage and bile congestion are dose-dependent and they are usually decreased after the discontinuation of treatment.
Rare (may affect up to 1 in 1,000 people)
Although changes in the blood count usually occur at the start of therapy, they can also occur later, during the therapy. Therefore, a regular check of blood cell count is advised even for patients who remain stable, during long-term treatment
Very rare (may affect up to 1 in 10,000 people)
A variety of reactions of possibly allergic origin have been reported. Signs of such hypersensitivity reactions can be feeling unwell, dizziness, drowsiness, nausea (feeling sick), vomiting, diarrhoea, fever, chills, skin rash, vascular inflammation, muscle and joint pain, drop in blood pressure, kidney and liver problems and blockage of the bile duct (biliary obstruction). In very rare cases, fatal hypersensitivity reactions have been reported
If you suffer from nausea with occasional vomiting, your doctor may ask you to take Jayempi after a meal to reduce these symptoms. Tell your doctor if you have severe diarrhoea or nausea and vomiting
Not known (frequency cannot be derived from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Jayempi contains
The active substance is azathioprine. One ml of suspension contains 10 mg azathioprine.
The other ingredients are sodium benzoate (E211), sucralose (E955), banana flavour, citric acid monohydrate, microcrystalline cellulose and carmellose sodium, xanthan gum and purified water. See section 2 Jayempi contains sodium benzoate and Jayempi contains sodium .
What Jayempi looks like and contents of the pack
Jayempi is a yellow, viscous oral suspension. It comes in glass bottles of 200 ml capped with a child- resistant closure. Each pack contains one bottle, a bottle adaptor and two dosing syringes (a syringe graduated to 3 ml and a syringe graduated to 10 ml). Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed
Marketing Authorisation Holder
Nova Laboratories Ireland Limited 3rd Floor Ulysses House Foley Street, Dublin 1 D01 W2T2 Ireland
Manufacturer Pronav Clinical Ltd. Unit 5 Dublin Road Business Park Carraroe, Sligo F91 DIreland
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-29e53310e209535224a929c7efb5c5b7
Resource Composition:
Generated Narrative: Composition composition-en-29e53310e209535224a929c7efb5c5b7
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1557/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - jayempi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp29e53310e209535224a929c7efb5c5b7
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp29e53310e209535224a929c7efb5c5b7
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1557/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Jayempi 10 mg/ml oral suspension
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en